EUCTR2013-002742-37-FR进行中（未招募）1 期
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - MATEO (Maintenance Teysuno in esophagogastric carcinoma)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 297
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent incl. participation in translational research
- •2. Male or female patient 18 years or older
- •3. Histologically confirmed metastatic or locally advanced unresectable gastric adenocarcinoma or adenocarcinoma of the esophagus or the esophagogastric junction (Her-2/neu negative or with unknown Her-2/neu status)
- •4. Measurable disease as per RECIST 1.1 criteria
- •5. Adjuvant/neoadjuvant or perioperativechemotherapy or (chemo-)radiotherapy must have been finished at least 6 months before study entry
- •6. No previous systemic treatment (i.e.chemotherapy) for metastatic disease
- •7. ECOG Performance Score 0-1 (Karnofsky Performance status >= 80%)
- •8. Ability for oral intake of the study drug, patients with tumor-related problems with oral intake might be registered if the symptom is expected to be improved during induction therapy (e.g. due to a tumor stenosis)
- •9. Female patient of childbearing potential (i.e.did not undergo surgical sterilization – hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and is not post-menopausal for at least 24 consecutive months) with a negative pregnancy test
- •10. Hematology and biochemistry laboratory results within the limits normally expected for the patient population, defined by the following:
- •Absolute neutrophil count =1500/µl
- •Platelet count =100000/µl
- •Leukocyte count > 3000/µl
- •Hemoglobin = 9 g/dL or 5.59 mmol/l, previous transfusions (>3 days) of erythrocytes are allowed
- •Total bilirubin = 1.5times the upper limit of normal (ULN), in patients with known Meulengracht syndrom =3 x ULN
- •AST = 3xULN in absence of liver metastases, or =5xULN in presence of liver metastases
- •ALT = 3xULN in absence of liver metastases, or =5xULN in presence of liver metastases
- •Creatinine clearance =30 mL/min according to Cockcroft-Gault formula
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous major sugery within the last 28 days before the start of the induction treatment. The implantation of a central venous access (e.g. porth-a cath system) is allowed.
- •2. History of other malignant tumors within the last 5 years, except basal cell carcinoma or curatively excised cervical carcinoma in situ
- •3. Known brain metastases
- •4. Concurrent radiotherapy involving target lesions used for this study. Concurrent palliative radiation for non-target lesions is allowed if other target lesions are available outside the involved field; previous radiotherapy including target lesions must have been finished at least 28 days before start of induction treatment.
- •5. Previous systemic treatment (i.e. chemotherapy) for metastatic disease
- •6. Known active HBV, HCV infection or documented HIV infection
- •7. Serious concomitant disease or medical condition that by judgment of the Investigator renders the patient at high risk of treatment complications
- •8. Clinically relevant coronary artery disease (NYHA functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the last 3 months, or high risk of uncontrolled arrhythmia
- •9. Female patient pregnant or breast feeding
- •10. Female patient of childbearing potential (i.e. did not undergo surgical sterilization – hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and is not post-menopausal for at least 24 consecutive months) not willing to use an adequate method of contraception to avoid pregnancy throughout the study and for up to 26 weeks after the end of treatment. Male patient not willing to use an adequate method of contraception to avoid conception throughout the study and for up to 26 weeks after the end of treatment in such a manner that the risk of pregnancy is minimized.
- •11. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 60 days prior to start of induction
- •12. Chronic diarrhea or short bowel syndrome
- •13. Known hypersensitivity to S-1, other fluoropyrimidines or platinum compounds.Contraindication to receive S-1 or the polychemotherapy (induction & arm B) chosen for this patient as per current Summary of Product Characteristics. Known DPD decifiency
- •14. Grade =2 peripheral neuropathy
- •15. Known drug abuse/alcohol abuse
研究者
相似试验
进行中（未招募）
1 期
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancermetastatic esophagogastric cancerEUCTR2013-002742-37-BEAIO-Studien-gGmbH400
进行中（未招募）
不适用
Clinical Trial for maintenance treatment with S-1 in cancer of esophagus or gastric metastatic after Induction chemotherapy.metastatic esophagogastric cancerEUCTR2013-002742-37-ESAIO-Studien-gGmbH297
进行中（未招募）
1 期
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancermetastatic esophagogastric cancerEUCTR2013-002742-37-SEAIO-Studien-gGmbH400
进行中（未招募）
1 期
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancermetastatic esophagogastric cancerEUCTR2013-002742-37-DEAIO-Studien-gGmbH400
进行中（未招募）
1 期
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancermetastatic esophagogastric neoplasiaEUCTR2013-002742-37-ATAIO-Studien-gGmbH297